<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026658</url>
  </required_header>
  <id_info>
    <org_study_id>VDAP-1002</org_study_id>
    <nct_id>NCT05026658</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study</brief_title>
  <official_title>A Prospective, Randomized, Controlled Clinical Study to Evaluate the Agreement and Reproducibility of Visibly Digital Acuity Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Visibly</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Visibly</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Visual acuity is the relative ability of the eye to resolve detail that is usually expressed&#xD;
      as the reciprocal of the minimum angular separation in minutes of two lines just resolvable&#xD;
      as separate and that forms in the average human eye an angle of one minute.&#xD;
&#xD;
      Visibly Inc. has developed a method for determining a patient's visual acuity electronically&#xD;
      via a web-based software system that can be self-administered wherever convenient. This&#xD;
      method provides an efficient alternative for people to have immediate access to visual acuity&#xD;
      measurements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Visibly Digital Acuity Product (VDAP) is a web-based, self-guided software application&#xD;
      intended for use by adults, ages 22 to 40, at home, to evaluate visual acuity with or without&#xD;
      correction. The standalone software application allows the user to interface with the&#xD;
      software via a web browser on two internet-enabled devices:&#xD;
&#xD;
        -  A computer screen (the Display) which displays optotypes&#xD;
&#xD;
        -  A touchscreen mobile device (the Remote) which operates as a remote control and&#xD;
           interface for the user to respond to prompts related to the optotypes appearing on the&#xD;
           Display while standing 10 feet away&#xD;
&#xD;
      The software allows users to view and respond to displayed optotypes and uses the responses&#xD;
      to categorize a user's visual acuity into one of two buckets:&#xD;
&#xD;
        -  20/25 or better&#xD;
&#xD;
        -  Worse than 20/25&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>The proportion of study eyes with VDAP VA of 20/25 or better 20/25 or better [Positive Predictive Value (PPV)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reproducibility</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>The proportion of study eyes which receive the same VA classification (20/25 or Better vs. Worse than 20/25) for the two VDAP tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>The proportion of subjects with matching VDAP and ETDRS VA classifications (20/25 or Better vs. Worse than 20/25) for both eyes (study eye and non-study eye)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>The proportion of subjects with matching VDAP VA classifications (20/25 or Better vs. Worse than 20/25) for the two VDAP tests for both eyes (study eye and non-study eye)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">358</enrollment>
  <condition>Digital Acuity Product</condition>
  <arm_group>
    <arm_group_label>Visibly Digital Acuity Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ETDRS Visual Acuity Lane Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Visibly Digital Acuity Product</intervention_name>
    <description>The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences:&#xD;
V1, E, V2&#xD;
E, V1, V2&#xD;
V2, E, V1&#xD;
E, V2, V1&#xD;
Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2.&#xD;
The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences.</description>
    <arm_group_label>ETDRS Visual Acuity Lane Test</arm_group_label>
    <arm_group_label>Visibly Digital Acuity Product</arm_group_label>
    <other_name>ETDRS Chart</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Be between 22 and 40 years (inclusive) of age at the time of consent 2. Be able and&#xD;
             willing to provide written informed consent, attend all scheduled visits and comply&#xD;
             with all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Have any of the following conditions (based on subject report):&#xD;
&#xD;
               1. Advanced eye disease in either eye;&#xD;
&#xD;
               2. Poor vision as a result of refractive surgery in either eye;&#xD;
&#xD;
               3. Unable to walk;&#xD;
&#xD;
               4. Unable to hear or follow audio instructions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Foley</last_name>
    <phone>217-971-4852</phone>
    <email>paul@govisibly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Foley</last_name>
      <phone>217-971-4852</phone>
      <email>paul@govisibly.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Core, Inc</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Foley</last_name>
      <phone>217-971-4852</phone>
      <email>paul@govisibly.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Total Eye Care</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Foley</last_name>
      <phone>217-971-4852</phone>
      <email>paul@govisibly.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

